Spinal Muscular Atrophy: Epidemiology Forecast to 2028

Research By Markets adds Market Research Report - Spinal Muscular Atrophy: Epidemiology Forecast to 2028

For detailed information: https://www.researchbymarkets.com/report/spinal-muscular-atrophy-epidemiology-forecast-to-2028-406686.html

Spinal Muscular Atrophy: Epidemiology Forecast to 2028

Summary

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by degeneration of alpha motor neurons in the spinal cord, resulting in progressive proximal muscle weakness and paralysis. The most common form of SMA is 5q SMA, linked to chromosome 5q and its phenotype is classified into four grades of severity (type I, type II, type III, and type IV) based on age of onset and motor function achieved (Amico et al., 2011). Additionally, SMA type 0 is an uncommon form of very severe SMA with prenatal onset (Finkel et al., 2015). In rare cases SMA is also caused by the mutation in another gene and known as non-5q SMA (Verhaart, Robertson, Wilson, et al., 2017).

Epidemiologists utilized historical data obtained from Orphanet, peer-reviewed articles, and population-based studies to build the forecast for the diagnosed prevalent cases of SMA in the 7MM. Epidemiologists applied the prevalence of SMA drawn from the above sources to each country’s population to calculate the number of estimated diagnosed prevalent cases for each subtype respectively.

The following data describes epidemiology of SMA. Epidemiologists forecast an increase in the diagnosed prevalent cases of SMA in the 7MM from 25,783 diagnosed prevalent cases in 2018 to 26,690 diagnosed prevalent cases in 2028, with an Annual Growth Rate (AGR) of 0.35% during the forecast period. The US will have the highest number of diagnosed prevalent cases of SMA among the 7MM, while Spain will have the lowest. In the 7MM combined, type II SMA made up the highest proportion of diagnosed prevalent cases of SMA and type IV made up the lowest proportion of diagnosed prevalent cases of SMA in 2018.

Scope

– The Spinal Muscular Atrophy Epidemiology Report provides an overview of the risk factors and global trends of Spinal Muscular Atrophy (SMA) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan).
– The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SMA segmented by sex (for all ages) in these markets. The diagnosed prevalent cases of SMA are further segmented by type (type I, type II, type III and type IV).
– The SMA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SMA Epidemiology report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global SMA market.
– Quantify patient populations in the global SMA market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SMA therapeutics in each of the markets covered.
– Understand magnitude of SMA population by its type.


For specific queries regarding this report: https://www.researchbymarkets.com/inquiry/406686

Contact Us:
ResearchByMarkets.com
Sales Desk
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchbymarkets/
Twitter: https://twitter.com/ResearchByMrkts

Market Research News brings the latest news and updates about the Industry.